Co-Authors
This is a "connection" page, showing publications co-authored by Fabrice Barlesi and Laurence Albiges.
Connection Strength
0.469
-
Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies. Ann Oncol. 2021 11; 32(11):1445-1447.
Score: 0.060
-
Severe COVID-19 in patients with hematological cancers presenting with viremia. Ann Oncol. 2021 10; 32(10):1297-1300.
Score: 0.060
-
Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. Cell Death Differ. 2021 12; 28(12):3297-3315.
Score: 0.060
-
Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic. Cancer Cell. 2021 08 09; 39(8):1039-1041.
Score: 0.059
-
Impact of COVID-19 on healthcare organisation and cancer outcomes. Eur J Cancer. 2021 08; 153:123-132.
Score: 0.059
-
Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. Cell Death Dis. 2021 03 11; 12(3):258.
Score: 0.058
-
Systematic Screening of COVID-19 Disease Based on Chest CT and RT-PCR for Cancer Patients Undergoing Radiation Therapy in a Coronavirus French Hotspot. Int J Radiat Oncol Biol Phys. 2021 07 15; 110(4):947-956.
Score: 0.058
-
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann Oncol. 2020 07; 31(7):961-964.
Score: 0.055